NATIONWIDE AVAILABILITY THROUGH
PHIL, CAREPOINT, AND ASPN PHARMACIES

Trudhesa® (dihydroergotamine mesylate) nasal spray | Official Healthcare Professional (HCP) Site | Impel NeuroPharma®

"Years of DHE results don't lie | Now they don't lie in wait"
"Years of DHE results don't lie | Now they don't lie in wait"

Ready to deliver relief3,4


Trudhesa® is the only acute treatment for migraine that uses advanced Precision Olfactory Delivery (POD®) technology to consistently deliver dihydroergotamine mesylate (DHE) to the vascular-rich upper nasal space, for rapid relief and sustained pain freedom, even when taken late in a migraine attack.2-4

Product image of Trudhesa® Precision Olfactory Delivery (POD®) vertical upright facing left

Exploratory end points and post hoc analyses of patient-reported efficacy data for some patients showed the following results4*:

Icon of Trudhesa®

Rapid

Pain relief in as fast as 15 minutes4

Icon of Trudhesa®

Sustained

Pain freedom lasted 2 days with 1 dose4

Icon of Trudhesa®

Consistent

Results delivered time after time3

Icon of Trudhesa®

Even late in an attack

Pain freedom on their terms, even when taken late into a migraine attack4-6

Product image of Trudhesa® Precision Olfactory Delivery (POD®) vertical upright facing left

*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa.4

Trudhesa Difference

Image of an actor portrayal of Trudhesa patient looking left down and smiling
Image of an actor portrayal of Trudhesa patient looking left down and smiling

References: 1. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(suppl 4):S212-S220. 2. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 3. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 4. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214-1226. 5. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 6. Data on File. Impel Pharmaceuticals. 2020.